Eric Venker - Feb 20, 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Stock symbol
ROIV
Transactions as of
Feb 20, 2025
Transactions value $
-$797,330
Form type
4
Date filed
2/24/2025, 09:00 PM
Previous filing
Feb 14, 2025
Next filing
Mar 24, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $385K +100K +11.15% $3.85 997K Feb 20, 2025 Direct
transaction ROIV Common Shares Sale -$1.07M -100K -10.03% $10.65 897K Feb 20, 2025 Direct F1
transaction ROIV Common Shares Tax liability -$117K -10.9K -1.22% $10.72 886K Feb 20, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -100K -0.91% $0.00 10.9M Feb 20, 2025 Common Stock 100K $3.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2 Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
F3 Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).